Recently, gene therapy company CombiGene signed an exclusive global license agreement for their gene therapy candidate CG01 with Spark Therapeutics. The deal is potentially worth $328.5 million excluding royalties. Much has happened since CombiGene was formed and BioStock turned to the scientific founders Professor Merab Kokaia and Associate Professor David Woldbye, for a comment on the company's development.

Read the full interview with Merab Kokaia and David Woldbye at biostock.se:

https://www.biostock.se/en/2021/10/combigenes-scientific-founders-on-the-agreement-with-spark/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/combigene/r/biostock-combigene-s-scientific-founders-on-the-agreement-with-spark,c3440147

(c) 2021 Cision. All rights reserved., source Press Releases - English